Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Matthew Langer Meyerson, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Matthew Meyerson and Heidi Greulich.
Connection Strength

3.913
  1. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A. 2012 Sep 04; 109(36):14476-81.
    View in: PubMed
    Score: 0.530
  2. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005 Nov; 2(11):e313.
    View in: PubMed
    Score: 0.329
  3. Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase. Nat Commun. 2021 07 16; 12(1):4375.
    View in: PubMed
    Score: 0.246
  4. Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12. J Biol Chem. 2020 03 13; 295(11):3431-3446.
    View in: PubMed
    Score: 0.222
  5. Optimization of PDE3A Modulators for SLFN12-Dependent Cancer Cell Killing. ACS Med Chem Lett. 2019 Nov 14; 10(11):1537-1542.
    View in: PubMed
    Score: 0.218
  6. Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics. Nat Chem Biol. 2016 Feb; 12(2):102-8.
    View in: PubMed
    Score: 0.167
  7. Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Mol Cancer. 2014 Jun 04; 13:141.
    View in: PubMed
    Score: 0.150
  8. Landscape of genomic alterations in cervical carcinomas. Nature. 2014 Feb 20; 506(7488):371-5.
    View in: PubMed
    Score: 0.145
  9. Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. Cancer Res. 2013 Nov 15; 73(22):6770-9.
    View in: PubMed
    Score: 0.143
  10. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012 Sep 14; 150(6):1107-20.
    View in: PubMed
    Score: 0.133
  11. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One. 2011; 6(6):e20351.
    View in: PubMed
    Score: 0.122
  12. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2011 Jun; 1(1):78-89.
    View in: PubMed
    Score: 0.122
  13. The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18; 463(7283):899-905.
    View in: PubMed
    Score: 0.111
  14. Somatic mutations are present in all members of the AKT family in endometrial carcinoma. Br J Cancer. 2009 Oct 06; 101(7):1218-9; author reply 1220-1.
    View in: PubMed
    Score: 0.108
  15. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A. 2008 Jun 24; 105(25):8713-7.
    View in: PubMed
    Score: 0.099
  16. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007 Dec 06; 450(7171):893-8.
    View in: PubMed
    Score: 0.095
  17. Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. . 2007 May; 6(5):661-7.
    View in: PubMed
    Score: 0.090
  18. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med. 2006 Jul; 12(7):852-5.
    View in: PubMed
    Score: 0.086
  19. Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors. Cold Spring Harb Symp Quant Biol. 2005; 70:73-81.
    View in: PubMed
    Score: 0.078
  20. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004 Jun 04; 304(5676):1497-500.
    View in: PubMed
    Score: 0.074
  21. Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. Nat Cancer. 2020 Feb; 1(2):235-248.
    View in: PubMed
    Score: 0.055
  22. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014 Apr; 124(4):1582-6.
    View in: PubMed
    Score: 0.037
  23. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. 2012 Aug 02; 488(7409):106-10.
    View in: PubMed
    Score: 0.033
  24. Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features. J Clin Oncol. 2011 Apr 10; 29(11):1415-23.
    View in: PubMed
    Score: 0.030
  25. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011 Apr 10; 29(11):1424-30.
    View in: PubMed
    Score: 0.029
  26. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010 Aug; 42(8):715-21.
    View in: PubMed
    Score: 0.029
  27. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell. 2010 Mar 16; 17(3):298-310.
    View in: PubMed
    Score: 0.028
  28. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest. 2009 Jun; 119(6):1727-40.
    View in: PubMed
    Score: 0.026
  29. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci U S A. 2009 Jan 13; 106(2):474-9.
    View in: PubMed
    Score: 0.026
  30. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008 Oct 23; 455(7216):1069-75.
    View in: PubMed
    Score: 0.025
  31. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008 Oct 16; 455(7215):975-8.
    View in: PubMed
    Score: 0.025
  32. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res. 2008 Jul 15; 68(14):5827-38.
    View in: PubMed
    Score: 0.025
  33. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008 Aug 07; 27(34):4702-11.
    View in: PubMed
    Score: 0.024
  34. The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev. 2008 Apr 01; 22(7):884-93.
    View in: PubMed
    Score: 0.024
  35. SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients. Genes Chromosomes Cancer. 2008 Mar; 47(3):253-9.
    View in: PubMed
    Score: 0.024
  36. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 2008 Feb 01; 68(3):664-73.
    View in: PubMed
    Score: 0.024
  37. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008 Feb 12; 105(6):2070-5.
    View in: PubMed
    Score: 0.024
  38. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 2007 Jun 15; 129(6):1065-79.
    View in: PubMed
    Score: 0.023
  39. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell. 2007 Mar; 11(3):217-27.
    View in: PubMed
    Score: 0.023
  40. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007 Mar; 39(3):347-51.
    View in: PubMed
    Score: 0.023
  41. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006 Dec; 3(12):e485.
    View in: PubMed
    Score: 0.022
  42. Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res. 2006 Jul 01; 66(13):6487-91.
    View in: PubMed
    Score: 0.022
  43. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res. 2006 Mar 15; 66(6):3162-8.
    View in: PubMed
    Score: 0.021
  44. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res. 2005 Oct 01; 65(19):8968-74.
    View in: PubMed
    Score: 0.021
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.